ATS Blue Journal
@ATSBlueEditor
Followers
20K
Following
442
Media
5K
Statuses
7K
Posting content from the American Journal of Respiratory and Critical Care Medicine; follows do not indicate endorsement. #pulmCC #sleepmed #AJRCCM #RespEd #ATS
Joined December 2014
📣Call for Papers! 📣 Looking for articles highlighting the spectrum of discovery in thoracic malignancies 📅Deadline: October 28, 2025 🔬Learn More Here: https://t.co/2GbPVXV5ul 🖱️Submit here: https://t.co/WBtyzclsPJ
@atscommunity @atstoa
0
4
5
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial @atscommunity 🔗 https://t.co/bbfNh81fWr
0
0
2
Softness. Fit. The right feel. But do your favorite pieces stay comfy after the first wash—or the tenth? At SHEIN, our fabrics are stretched, rubbed, steamed, and spun to test for lasting comfort and durability. Real quality is how pieces hold up over time, not just day one.
4
55
118
Hitting the Sweet Spot: The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis @atscommunity 🔓 Open Access 🔗
0
0
2
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study @atscommunity 🔗 https://t.co/B80KCZUvtT
1
2
6
Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis: No Longer “If” but a Question of “When” to Start @atscommunity 🔗
0
0
3
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study @atscommunity 🔗 https://t.co/Q1titvXwNT
0
2
10
Aging Gracefully: Does Elexacaftor/Tezacaftor/Ivacaftor Safety and Efficacy Stand the Test of Time? @atscommunity 🔓 Open Access 🔗
0
0
3
Collagen Post-Translational Modifications Are Altered in Idiopathic Pulmonary Fibrosis, Including within Extracellular Matrix Receptor Binding Motifs This study suggests that hydroxyproline underestimates fibrosis @atscommunity 🔗 https://t.co/awbvyrGMTv
0
1
1
Vaping is often advertised as harmless, but it has serious health effects, including worsening mental health. As expert @crottyalexander, of @UCSanDiego, explains to host @ErikaMosesonMD, MA, research shows that teens who vape have higher rates of depression and attempts at
2
6
6
Genetic Associations in Non-Europeans with Pulmonary Fibrosis: Analysis of the All of Us Cohort Key genetic risk factors of IPF are less prevalent in non-European individuals but confer similar risk of disease when present @DavidZhangMD 🔗 https://t.co/1rRIVHrVTU
0
3
3
📣Call for Papers! 📣 Looking for articles highlighting the spectrum of discovery in thoracic malignancies 📅Deadline: October 28, 2025 🔬Learn More Here: https://t.co/2GbPVXUxEN 🖱️Submit here: https://t.co/WBtyzckV0b
@atscommunity @atstoa
0
4
2
Sarcoidosis Resolvers and Progressors Demonstrate Distinct Systemic Metabolomic Profiles In subjects with sarcoidosis, the authors identified distinct serum metabolomic profiles present at the time of diagnosis that corresponded to clinical outcomes 🔗 https://t.co/MFa5yllPAc
0
1
3
The Blue Journal thanks Ling Sun, PhD, for his contribution to the October issue STAT3-Dependent Regulation of CFTR and Ciliogenesis Is Essential for Mucociliary Clearance and Innate Airway Defense in Hyper-IgE Syndrome https://t.co/mkf6pq9vVa
0
0
1
Spontaneous Pneumothorax as First Presentation of Pulmonary Alveolar Microlithiasis @atscommunity 🔗 https://t.co/9k5c2Z0KdE
0
2
10
📰 AJRCCM IN THE NEWS See research from AJRCCM highlighted in the New York Times article, "A Coal-Processing Plant Closed. Local E.R. Visits Dropped Sharply." 🔗 https://t.co/N5PkAkp0Y3 Read the paper here: https://t.co/yK3wvfJUk2
@atscommunity
nytimes.com
As President Trump tries to revive the United States coal industry, research has found that closing a coal facility can improve local health.
1
2
5
A 10,000-Foot View at Survival and Treatment with Phosphodiesterase-5 Inhibitors in Interstitial Lung Disease Pulmonary Hypertension 🔓 Open Access 🔗 https://t.co/PMEBXwdckG
0
1
3
The Blue Journal thanks Feng Yuan, PhD, for his contribution to the October issue Ionocyte Cystic Fibrosis Transmembrane Conductance Regulator Coordinates Chloride Absorption and Secretion to Balance Airway Fluid https://t.co/pqY4M3I6UQ
0
0
3
Breaking Barriers: Enhancing Access, Equity, and Efficiency in Interstitial Lung Disease Clinical Trials @atscommunity 🔓 Open Access 🔗 https://t.co/EvHc9UGeLx
1
2
9
What role does AI play in training the next generation of doctors? As @KaeleLeonard, MD, of @VUmedicine, explains on the latest episode of the ATS Breathe Easy podcast, there's still value to learning to do procedures without AI assistance. Watch the full episode now or tune in
0
6
6
The Blue Journal thanks Jonathan Rayment, MDCM, MSc, FRCPC, for his contribution to the October issue Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele https://t.co/DPDuzgYOaH
0
0
2
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis Standalone lung function decline provides better mortality discrimination and similar net benefit for antifibrotic initiation than PPF guideline criteria 🔗 https://t.co/Vfmtggu2bY
0
0
2